Literature DB >> 7750075

Pyridoxine dependent epilepsy with iatrogenic sensory neuronopathy.

R S McLachlan1, W F Brown.   

Abstract

An 18-year-old man was treated from birth with chronic high dose pyridoxine (vitamin B6) up to 2000 mg per day for pyridoxine-dependent seizures. Within two years of onset of treatment, he developed a sensory neuropathy which did not progress over the following 16 years. Electrophysiological studies were consistent with a pure sensory neuronopathy expressed as centripetal degeneration of processes of the dorsal root ganglion cells.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7750075     DOI: 10.1017/s0317167100040506

Source DB:  PubMed          Journal:  Can J Neurol Sci        ISSN: 0317-1671            Impact factor:   2.104


  5 in total

1.  Long-Term Follow-up of a Successfully Treated Case of Congenital Pyridoxine-Dependent Epilepsy.

Authors:  Malcolm Proudfoot; Philip Jardine; Agne Straukiene; Rupert Noad; Andrew Parrish; Sian Ellard; Stuart Weatherby
Journal:  JIMD Rep       Date:  2013-02-12

2.  Current treatment and management of pyridoxine-dependent epilepsy.

Authors:  Clara D M van Karnebeek; Sravan Jaggumantri
Journal:  Curr Treat Options Neurol       Date:  2015-02       Impact factor: 3.598

3.  Pyridoxal phosphate is better than pyridoxine for controlling idiopathic intractable epilepsy.

Authors:  H-S Wang; M-F Kuo; M-L Chou; P-C Hung; K-L Lin; M-Y Hsieh; M-Y Chang
Journal:  Arch Dis Child       Date:  2005-05       Impact factor: 3.791

4.  High-dose pyridoxine and magnesium administration in children with autistic disorder: an absence of salutary effects in a double-blind, placebo-controlled study.

Authors:  R L Findling; K Maxwell; L Scotese-Wojtila; J Huang; T Yamashita; M Wiznitzer
Journal:  J Autism Dev Disord       Date:  1997-08

5.  Clinical features and the management of pyridoxine-dependent and pyridoxine-responsive seizures: review of 63 North American cases submitted to a patient registry.

Authors:  Gregory J Basura; Shawn P Hagland; Anna M Wiltse; Sidney M Gospe
Journal:  Eur J Pediatr       Date:  2008-09-02       Impact factor: 3.183

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.